The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to ...
Apr 16, 2018
0
6
Two different proteins work separately as well as synergistically to feed a small pool of stem cells that help bladder cancer resist chemotherapy, research led by a Johns Hopkins Kimmel Cancer Center scientist suggests. The ...
Jan 24, 2018
0
17
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
Jan 17, 2018
0
20
Even as treatment options for laryngeal cancer seemed to improve, survival rates did not. For the most advanced patients, 50 percent survival was the norm, whether patients had surgery to totally remove the voice box or alternative ...
Feb 2, 2017
0
0
The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress ...
Oct 8, 2016
0
4
Osteosarcoma patients with tumors that haven't responded well to the standard chemotherapy regimen have unimproved outcomes and more side effects when given two additional drugs, a large international trial has found.
Aug 26, 2016
0
0
(HealthDay)—Models based on machine learning and optimization could improve chemotherapy regimens to be tested in phase III clinical trials without altering the toxicity outcomes, according to a study published in the May ...
May 9, 2016
0
1
The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug combination netupitant/palonosetron (trade name: Akynzeo) offers an added benefit over the appropriate ...
Nov 23, 2015
0
0
(HealthDay)—Chemotherapy at the start of hormone therapy can extend the lives of men with prostate cancer that has spread beyond the gland, a new study finds.
Aug 6, 2015
0
32
For more than a decade, oncologists using cytotoxic chemotherapy to treat patients with advanced metastatic castration-resistant prostate cancer (mCRPC) have relied on the sequential use of single agent taxanes such as docetaxel ...
May 31, 2015
0
17
